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Abstract
Among the hepatotropic viruses, hepatitis C virus (HCV) is considered to be the leading cause of liver disease in humans, affecting f 2%
of the world population. HCV-encoded nonstructural protein 5A (NS5A) is a 56–58-kDa phosphoprotein, which is produced from the
processing of viral polyprotein. The potential mechanism(s) by which NS5A is able to influence key cellular processes are largely unknown.
In this study, we investigated the functional properties of NS5A. In vivo co-immunoprecipitation and pull-down assays demonstrated that
NS5A forms a heteromeric complex with TATA box binding protein (TBP) and tumor suppressor protein p53. Mutants of TBP and p53
showed reduced binding to NS5A. To determine the functional relevance of these associations, we found that NS5A inhibits the binding of
both p53 and TBP to their DNA consensus binding sequences in vitro. NS5A also inhibited the p53–TBP and p53–excision repair cross
complementing factor 3 (ERCC3) protein–protein complex formation. Furthermore, NS5A repressed the p53 regulated p21 (WAF1)
promoter and a synthetic promoter containing multiple p53 responsive DNA elements binding sites in HCT116 p53+/ + cell line. p53-
mediated transcriptional activation from both promoters was reduced f3–5-fold following expression of NS5A.
Taken together, these results suggest that NS5A may exert its influence on key cellular processes by functional associations with p53 and
TBP. This could explain one of the possible mechanism(s) by which NS5A is able to exert its effect on cellular gene expression and cell
growth regulation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatitis C virus (HCV) infection is an emerging epidemic
causing severe liver disorders, but the molecular mechanisms
of HCV-induced liver injury remain largely elusive. End-
stage liver disease may develop in f 20% of chronically
infected individuals, in many cases requiring liver trans-
plantation. After prolonged chronic infections, approximately
1% to 5% develop hepatocellular carcinoma [5,42].
HCV is a positive-stranded RNAvirus distantly related to
the flaviviruses and pestiviruses [20,31]. Immediately fol-
lowing the 5Vnoncoding region (5VNCR), the gene order is
as follows: 5V-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-
NS5B–3V[21,31]. NS5A region encodes two phosphopro-
teins of f56 and 58 kDa [16,19,23,46]. Furthermore,
NS5A has shown to be phosphorylated in vitro by casein
kinase II and by c-AMP-dependant protein kinase A-alpha
catalytic subunit [17,19,23]. Several studies have identified
various functions of NS5A protein with potential implica-
tions for HCV pathogenesis and hepatocarcinogenesis
[1,9,12,14,21,30,45,50,56]. NS5A has also become a sub-
ject of intense investigation, due to the identification of an
interferon sensitivity-determining region (ISDR) within
NS5A [9,11]. NS5A protein contains a nuclear localization
signal sequence and has been localized both in cytoplasm
[18] and in the nuclear membrane fraction [46], indicating
its potential functions in both compartments of the cell.
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NS5A lacking an amino-terminal region strongly activates
transcription in yeast and human hepatoma Huh7 cells
[21,47]. Conflicting reports have emerged in describing
the role of NS5A in cell cycle and cell growth and its
associations with cellular proteins. While Ghosh et al. [12]
have reported that NS5A modulates the cell cycle regulatory
genes and promotes cell growth, Armia et al. [1] suggested
that NS5A causes growth inhibition and cell cycle perturba-
tion by targeting the Cdk1/2–cyclin complexes. Similarly in
a recent study, NS5A was shown to interact with tumor
suppressor protein p53 [30]. In contrast, Otsuka et al. [33]
reported that it is the core protein (C) of HCV, which
associates with p53, not NS5A.
The p53 activities have been implicated in cell cycle
control, transcriptional activation and repression, modula-
tion of factors engaged in DNA repair, apoptosis, and
antioxidant responses [16,27,24,29,34,40,48]. In addition,
p53 regulates transcription by binding with transcription
factors such as TATA box binding protein (TBP) [28],
TAFII40 and TAFII60 [48], excision repair cross comple-
menting factor 3 (ERCC3) subunit of transcriptional factor
IIH (TFIIH) [15,51], C/EBP (p300), SRC1 and ACTR
[16,29]. p53 inactivation is strongly correlated in most
forms of human cancer [15,16,27]. p53 induces the expres-
sion of a number of downstream targets, including
GADD45 [15,16,27], MDM2 [32], cyclin G and p21
(WAF1/CIP1) [6]. It is the up-regulation of p21 which is
linked with cell cycle arrest [43]. Interestingly, p53 also
represses the transcription of some genes, which is corre-
lated with its ability to induce apoptosis [34,55].
In this report, we show the functional association of
NS5A with TBP and further evaluate the implications of
NS5A–p53 interactions. Protein affinity chromatography,
gel mobility shift analysis and transfection were used to
show that NS5A directly binds to TBP and p53 and inhibits
their binding to DNA. The NS5A binding to p53 also
interferes in the ability of p53 to recognize TBP and
ERCC3. Furthermore, NS5A inhibited the p53 responsive
promoter activities in vivo.
2. Experimental procedures
2.1. Materials
2.1.1. Cell lines
Rat hepatoma FAO, human epithelial HCT/116 p53+/ +
(p53-overexpressing) and HCT116 p53 / (p53-deficient)
cell line [2,22] (Dr.Vogelstein) were grown as a monolayer
for transfections and/or cell fractions for protein–protein
interaction studies, Western blotting and electrophoretic
mobility shift assay (EMSA).
2.1.2. Plasmids
NS5A expression plasmids pCDNA/NS5A (mammalian)
and pGST–NS5A (bacterial) were obtained from Dr. Katze,
Seattle, which were originally isolated from HCV strain 1b
[14,45]. pRC/TBP for expression of hTBP has been
described [35]. p53 mammalian expression vector pCMV–
p53 and its mutants, p53V143A, p53R175H, p53R248Wand
p53R273H [2,22], were a gift from Dr.Vogelstein. p53–LUC
was constructed by inserting a 140-bp Sma1 fragment
encompassing seven copies of p53 consensus binding sites
(5V-gaacatgttaggacatgttc-3V) in pGL3-basic (Promega). The
same p53 consensus DNA was used in the EMSA. TBP
consensus probe (5V-gcagagcaTATAggtgaggtagga-3V) was
used in the EMSA. pWWP–LUC containing the 2.1-kb
p21 promoter with the reporter luciferase gene [6] was
obtained from Dr. El-Diery, Philadelphia. ERCC3 expression
plasmid was obtained from Dr. Hoijemaker, Netherlands.
2.1.3. Antibodies
Monoclonal Ab-6 for p53 and NS-5 for NS5Awere from
Oncogene and ID Labs, respectively. a-ERCC3 was a gift
from Dr. Sancar, North Carolina. a-TBP was from Santa-
Cruz Labs.
3. Methods
3.1. Protein–protein interactions
Cells were washed twice in cold PBS and lysed at + 4 jC
in buffer containing 150 mM NaCl, 20 mM Tris/pH 7.4, 1
mM EDTA, 0.1% SDS, 1% NP-40, 10 mM p-nitrophenol-
phosphate, 10 mM sodium fluoride, 40 mM glycerophos-
phate and 1 mM phenylmethylsulfonyl fluoride (PMSF).
Nuclear extracts were prepared as described [36]. Both
fractions were mixed and dialyzed against buffer containing
50 mM KCl, 10 mM Tris/pH 7.4, 1 mM EDTA, 1 mM DTT,
10% (vol/vol) glycerol and 1 mM PMSF. Whole-cell
extracts were used for immunoprecipitation and affinity
chromatography. The bound fractions were resolved by
7.5% SDS-PAGE, transferred to nitrocellulose filters
(Schleicher and Schuell) and probed with a-TBP, a-NS5A
or a-p53 using the ECL system (Amersham).
Cell lysates were allowed to pass through gluthathione S-
transferase (GST)-affinity resin (Pharmacia), which were
immobilized with either 10 mg of GST or GST–NS5A
protein and allowed to interact for 2 h at 4 jC with rocking
in buffer A, containing 100 mM KCl, 20 mM Tris–HCl, pH
8.0, 0.1 mM EDTA, 0.1% NP40, 1 mM dithiothreitol, 10%
glycerol and protease inhibitors. GST affinity beads were
extensively washed with buffer A containing 450 mM KCl.
3.2. Affinity chromatography
35S-labeled NS5A, TBP, p53 and ERCC3 proteins (5 Al
of 50 Al) were chromatographed through 20-Al microaffinity
column containing immobilized (Affi-gel 10: Bio-Rad) GST
and GST-fusion proteins at a 2 mg/ml protein concentration
in buffer A (10 mM HEPES [pH 7.5], 0.15 M KCl, 1 mM
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ATP, 1 mM EDTA, 10% glycerol, containing 2 mg of
bovine serum albumin and 0.1% Nonidet P40. Affinity
columns were washed with buffer A and bound fractions
eluted in buffer A containing 0.5 M KCl and 1% SDS. GST-
fusion proteins were extracted from bacterial cultures as
described previously [35].
3.3. In vitro protein synthesis
TBP and NS5A were translated in vitro from plasmids
pRC/TBP and pCDNA/NS5A by using T7 RNA polymer-
ase, 35S-[methionine] and TNT rabbit lysates (Promega). A
series of sequential deletion mutants of TBP was translated
in vitro after digesting pRC/TBP with PstI (aa 110), BspH1
(aa 177), SspI (aa 210) and Stu1 (aa 281). ERCC3 and p53
were translated from pCMV/p53 and pRC/ERCC3, respec-
tively.
3.4. Gel EMSA
The oligonucleotides were radiolabeled with [g32P]dATP
using T4 polynucleotide kinase. Binding reaction mixtures
contained 20 mM HEPES (pH 7.9), 4% Ficoll type 400, 50
mM KCl, 0.5 mM EDTA, 100 Ag of poly(dI–dC), 50 ng of
pSK+ DNA (Stratagene) and 20,000 cpm of DNA probe.
Reaction mixtures were incubated at 25 jC for 30 min, with
DNA, nuclear extract and purified GST–NS5A. The com-
plexes were separated by electrophoresis in 4.5% native
polyacrylamide gel at 120 V at 4 jC in 0.5 TBE buffer.
3.5. DNA transfections
Cultures were set up 24 h prior to transfections in 35-mm
6-well plates at 106 cells/well in McCoys media with 10%
fetal calf sera and were transfected using lipofectamine 2000
(Gibco), 3:1 lipid to DNA ratio. pGL3–LUC (1.0 Ag) and
p53–LUC (1.0 Ag) were used; 0.5 Ag of pCDNA/NS5Awas
used along with 0.05 Ag of pRL-null per well; 0.5 Ag each
of pCDNA3.1 (empty vector) was also added in pGL3–
LUC and p53–LUC transfections (Fig. 9A); 2.0 Ag of
pCDNA3.1 (empty vector) was added in WWP–LUC
(p21 promoter) activity experiment (Fig. 9B). Post-trans-
fection cells (48 h) were harvested and assayed for lucifer-
ase activity using dual luciferase reporter assay system
(Promega).
4. Results
4.1. NS5A binds with TBP and p53 in cellular extracts
Protein affinity chromatography was employed to iden-
tify the potential cellular partners of NS5A from rat liver-
Fig. 1. NS5A associates with p53 and TBP in cellular extracts. (A) 35S-
[methionine]-labeled FAO cell extract was passed through glutathione
affinity column immobilized with either GST or GST–NS5A and after
extensive washing separated on 7.5% SDS-PAGE, followed by auto-
radiography. Arrows indicate the position of two polypeptides which were
further characterized by immunoblotting. (B) Immunobloting of GST and
GST–NS5A bound unlabeled proteins using either a-p53 or a-TBP. The
bound fractions were separated on 7.5% SDS-PAGE, followed by ECL
detection of the expected bands.
I. Qadri et al. / Biochimica et Biophysica Acta 1592 (2002) 193–204 195
derived FAO hepatoma cell extracts. In the first approach,
35S-labeled extracts were prepared and chromatographed on
a glutathione affinity column immobilized with either GST
or GST–NS5A. The bound fractions were separated on
7.5% SDS-PAGE (Fig. 1). Approximately 12 polypeptides
bound to GST–NS5A (Fig. 1A, lane 2) while one back-
ground band of f50 kDa bound to GST (lane 1). The
rationale for the further analysis of f 38- and 53-kDa
bands was based entirely on the availability of several
antibodies within these ranges. FAO cell extracts were
prepared from 100 confluent plates (100 mm) and 200 mg
of total proteins were allowed to interact with glutathione
affinity beads immobilized with either GST or GST–NS5A.
The bound fractions were separated by 7.5% SDS-PAGE,
followed by immunoblotting with a number of available
antibodies against the known proteins of f 33–40
andf 50–53 kDa, shown by arrows in Fig. 1A. Antibodies
against cellular proteins including CDC2 (p35), PCNA
(p36), TFIIB (40 kDa), TBP (38 kDa), C/EBPh (58 kDa),
C-fos (53 kDa), thyroid hormone receptor (53 kDa), p53 (53
kDa) and TFIIH subunit (61 kDa) were used. Only a-TBP
and a-p53 positively identified the expected bands as TBP
and p53, respectively (Fig. 1B, lane 2). Next, a series of in
vitro and in vivo approaches was taken to further confirm
NS5A–TBP and NS5A–p53 associations.
4.2. Analysis of NS5A–TBP binding
4.2.1. NS5A interacts with TBP in vitro
The cDNA encoding various components of general
transcriptional factor (GTF) including, hTBP, hTFIIB,
hTFIIE (a and h subunits) and all the known nine subunits
of yeast TFIIH were labeled in vitro with 35S-[methionine].
The radiolabeled proteins were allowed to interact with
glutathione affinity beads immobilized with either GST or
GST–NS5A fusion protein. After extensive washing, the
bound fractions were separated by SDS-PAGE, as described
previously [36]. These results show that HCV NS5A spe-
cifically interacts with TBP (Fig. 2A, lane 1). No binding
was seen with TFIIB (lane 2), TFIIE a and h subunits (lanes
3 and 4), any subunit of TFIIH (data not shown) and GST
(data not shown).
In an alternative approach, NS5A protein was labeled
with 35S-[methionine] and allowed to interact with affinity
beads immobilized with GST–hTBP [35] (Fig. 2B). Results
showed a specific interaction between NS5A and TBP and
were consistent with the earlier observation (Fig. 2A). To
further confirm TBP–NS5A interactions, we also performed
cross-immunoprecipitation using either antibodies against
TBP or FLAG epitope tagged to NS5A at the C terminus.
35S-labeled TBP and NS5A–FLAG proteins were mixed
and co-immunoprecipitated using either TBP or FLAG
antibodies (Fig. 2C). No cross-reactivity of TBP and FLAG
antibodies was seen (Fig. 2C, lanes 2 and 4). However,
either TBP or FLAG antibody was able to co-immunopre-
cipitate the NS5A and TBP complexes, by virtue of their
Fig. 2. Associations of NS5A with TBP (A) 35S-[methionine]-labeled TBP,
TFIIB, TFIIEa and TFIIEh interaction with GST–NS5A. Bound fractions
are shown in lane 1, TBP; lane 2, TFIIB; lane 3, TFIIEa; and lane 4, TFIIh.
One-tenth of input for each experiment is shown. (B) 35S-[methionine]-
labeled NS5A’s interaction with GST (lane 1) and GST-hTBP (lane 2).
Lanes 3 and 4, input NS5A. (C) Cross-immunoprecipitation of 35S-TBP and
35S-NS5A complexes using either a-TBP or a-FLAG. Flag epitope was
inserted at the carboxyl terminus of NS5A for this study. Lanes 1 and 3,
positive controls for TBP and NS5A antiserum, respectively. Lanes 2 and 4,
negative controls for NS5A and TBP antiserum, respectively. Lanes 5 and
6, TBP and NS5A complexes immunoprecipitated by either a-TBP or a-
FLAG.
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associations (lanes 5 and 6). These results further confirm
the authenticity of TBP–NS5A complexes.
4.2.2. The carboxy-terminal half of TBP is critical for
binding to NS5A
To identify the domains of TBP involved in its inter-
action with NS5A, carboxy-terminal deletions of TBP were
generated using restriction endonucleases (RE). PstI, SspI,
BspH1 and StuI were used to cleave pRC/TBP for generat-
ing TBP carboxyl-terminus truncations at aa positions 110,
177, 210 and 281, respectively. 35S-labeled TBPwt and
TBPmut proteins were incubated with beads immobilized
with either GST or GST–NS5A. TBPwt is added in the
binding reaction to serve as a positive control for affinity
with GST–NS5A (lanes 2, 4, 6 and 8) and as a negative
control for affinity with GST alone (lanes 1, 3, 5 and 7).
This approach has been published previously [35]. The
results shown in Fig. 3A indicate that TBP encompassing
aa 1–281, but lacking the C-terminal 74 aa, still binds with
NS5A (lane 2). However, further truncations of carboxyl
terminus (145 aa or larger) abrogated interactions with
NS5A (lanes 4, 6 and 8), suggesting the importance of
210 to 281 residues of TBP for interaction with NS5A. The
functional implication of NS5A–TBP interactions in the
context of transcriptional regulation remains to be inves-
tigated. Next, we examined the functional relevance of
p53–NS5A associations.
4.3. Analysis of NS5A–p53 binding
4.3.1. Wild type and p53 mutants interact with NS5A in vitro
To further confirm NS5A–p53 associations, p53wt was
labeled with 35S-[methionine] and allowed to interact with
GST–NS5A. NS5A specifically interacted with p53, while
no binding with GST occurred (Fig. 4, lanes 6 and 1,
respectively).
Fig. 3. (A) Associations of full-length TBP and its carboxyl-terminus deletion mutants with NS5A. The binding of TBP and its mutants lacking 74, 145, 178
and 245 amino acids to either GST (lanes 1, 3, 5 and 7, respectively) or GST–NS5A (lanes 2, 4, 6 and 8, respectively). Full-length TBP was added as a positive
control in the binding reaction. Only TBP mutant lacking 74 amino acids bound with GST-NS5A (lane 2). (B) One-tenth of the 35S-labeled input TBP and its
mutant proteins are shown.
Fig. 4. Associations of p53 and its point mutants with NS5A. Wild-type p53
and its mutant V143-A, R175H, R248S, R278H proteins were translated in
vitro and labeled with 35S-[methionine]. Radiolabeled p53wt and p53mut
proteins were allowed to interact with either GST (lane 1) or GST–NS5A
(lanes 2–6). No binding was seen with GST (lane 1). A specific interaction
between NS5A and p53 was observed (lane 6). p53 mutants R175H (lane
3), R248S (lane 4) and R273H (lane 5) interacted with GST–NS5A with
equal affinities like p53wt (lane 6). p53 mutant V143A showed significantly
reduced binding to GST–NS5A (lane 2). Lower molecular weight band of
f 45 kDa indicated a translated product from p53 transcripts with an
internal initiation site which failed to interact with NS5A (A, lanes 2–6).
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4.3.2. p53 mutant V143A showed significantly less inter-
action with NS5A
Radiolabeled p53 mutant proteins p53V143A, p53
R175H, p53R248S and p53R273H were allowed to interact
with GST–NS5A (lanes 2–6). p53V143A with substitution
of Val to Ala residue at the N-terminal core domain of p53
showed significantly less binding to GST–NS5A (Fig. 4,
lane 2). Other p53 mutants, R175H, R248W and R273H
interacted with GST–NS5A with equal affinities (lanes 3–
5). It is important to note that the lower molecular weight
bands of p53 derivatives with internal initiation sites (lack-
ing N-terminus of p53) failed to interact with NS5A. This
observation is consistent with the results of p53 point
mutant V143A described above and the recently published
results [30], suggesting the importance of the N terminus of
p53 for interaction with NS5A.
4.4. NS5A inhibits p53 and TBP binding to their consensus
DNA probes
Next, we investigated the effect of NS5A on the DNA-
binding activities p53 and TBP by EMSA. First, EMSAwas
performed using p53 consensus binding DNA and nuclear
Fig. 5. NS5A prevents the binding of p53 to its consensus DNA sequence.
EMSA of p53 and p53 consensus binding DNA, using 20 Ag of HCT116
p53+/ + nuclear extracts (lanes 2–10 and 12). Lane 11 contains 20 Ag of
nuclear extracts from HCT116, p53 /  cell line. Lane 1, free probe. Lane
2, without exogenous protein added. Lanes 3 and 4 contain 500 ng of
bacterially purified GST and GST–STAT5b proteins, respectively. Lanes
5–9 contain increasing concentrations (10, 50, 100, 200 and 500 ng,
respectively) of bacterially purified GST–NS5A. The GST-fusion proteins
were added to the nuclear extracts prior to addition of radiolabeled DNA.
Increasing amounts of NS5A, 50 ng (lane 6), 100 ng (lane 7) and 200 ng
(lane 8) significantly reduced the binding of p53 to DNA and at 500 ng this
binding was abolished (lane 9). Addition of 500 ng of GST alone (lane 3) or
unrelated GST-fusion protein GST–STAT5b (lane 4) had no effect on
binding. p53 antibody specifically supershifted the p53–DNA box complex
(lane 10), and an unrelated antibody a-STAT5b had no effect on the
supershift (lane12). p53 / nuclear extracts showed no binding to the p53
consensus DNA (lane 11). F: free p53 consensus DNA binding probe; C:
p53–DNA complex; and SS: supershifted p53–DNA band with a-p53.
Fig. 6. NS5A interfere in TBP binding to TATA box containing DNA.
EMSA of TBP and TATA box DNA in the presence of NS5A using TBP-
enriched HeLa nuclear extracts (Promega). Lanes 2–13 (with the exception
of lane 11) each contain 1 Al of HeLa nuclear extracts. Lane 1, free probe.
Lane 2, without exogenous protein. Lanes 3 and 4 contain 500 ng of
bacterially purified GST and GST–STAT5b proteins, respectively. Lanes
5–9 contain increasing concentrations (10, 50, 100, 200 and 500 ng,
respectively) of bacterially purified GST–NS5A. The GST-fusion proteins
were added in the HeLa nuclear extracts prior to addition of radiolabeled
DNA. Increasing amounts of NS5A, 100 ng (lane 7), 200 ng (lane 8) and
500 ng (lane 9) significantly reduced the binding of TBP protein to TATA
box DNA, while the addition of 500 ng of GST alone (lane 3) or unrelated
GST-fusion protein GST–STAT5b (lane 4) had no effect on binding. TBP
antibody specifically supershifted the TBP–TATA box complex (lane 10),
and unrelated antibodies a-STAT5b had no effect on the supershift (lane12).
TBP antibody did not bind to the TBP probe alone in the absence of nuclear
extracts (lane 11); 10 cold TATA box DNA competed in the binding
reaction (lane 13). F: free TATA box DNA probe; C: TBP–TATA box DNA
complex; and SS: supershifted TBP–TATA box band with a-TBP.
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extracts from HCT116 p53+/ + and p53 / cell lines (Fig.
5). Increasing concentrations (10, 50, 100, 200 and 500 ng)
of GST–NS5A fusion protein were added in the nuclear
extracts prior to addition of radiolabeled DNA (lanes 5–9,
respectively). GST (500 ng) (lane 3) or an unrelated GST-
fusion protein GST–STAT5b (lane 4) was added as control.
Increasing amounts of NS5A, 50 ng (lane 6), 100 ng (lane 7)
and 200 ng (lane 8) significantly reduced the binding of p53
protein to p53 consensus DNA and at 500 ng of GST–
NS5A this binding was abolished (lane 9). While the
addition of 500 ng of GST alone (lane 3) or GST–STAT5b
(lane 4) had no effect on binding, a-p53 specifically super-
shifted the p53–DNA complex (lane 10), and an unrelated
antibody a-STAT5b had no effect on the supershift (lane12).
p53 / nuclear extracts showed no shift to the p53 con-
sensus DNA (lane 11). These results further confirm the
specificity of p53–DNA complexes.
Next, TBP–TATA box EMSA was performed, in the
presence of NS5A and using TBP-enriched HeLa nuclear
extracts (Promega). Increasing concentrations (10, 50, 100,
200 and 500 ng) of GST–NS5A fusion proteins were added
in the HeLa nuclear extracts prior to addition of radiolabeled
DNA (Fig. 6). Addition of 100 and 200 ng of GST–NS5A
significantly reduced the binding of TBP protein to TATA
box DNA, (lanes 7 and 8). At 500-ng concentration of
GST–NS5A, this binding was abolished (lane 9), while the
addition of 500 ng of GST alone (lane 3) or unrelated GST-
fusion protein GST–STAT5b (lane 4) had no effect on
binding. TBP antibodies supershifted the TBP–TATA box
complex (lane 10), suggesting the specificity of TBP–TATA
box complex. Unrelated antibodies a-STAT5b had no effect
on supershift (lane12). TBP antibodies did not bind to the
TBP probe alone in the absence of nuclear extracts (lane
11). Cold TATA box DNA (10 ) competed in the binding
reaction (lane 13).
These results unequivocally confirm the authenticity of
TBP–TATA box and p53–DNA complexes which were
inhibited by NS5A. Next, we examined the ability of NS5A
to influence p53 interactions with cellular TBP and ERCC3
proteins.
4.5. Effect of NS5A on associations of p53 with ERCC3 and
TBP
4.5.1. NS5A interferes in the binding of p53 to ERCC3
p53 is thought to modulate cellular gene transcription
by association with TBP [24,28] and ERCC3 component
of TFIIH [26]. ERCC3, p53wt and its mutants were
translated in the presence of 35S-[methionine] and allowed
to interact each other either in the absence or presence of
NS5A (Fig. 7, lanes 1–14). This was followed by co-
immunoprecipitation using ERCC3 and p53 antibodies.
Previously, p53 mutants are shown to abrogate p53 bind-
ing to DNA and/or its oligomerization [2,16,22], however,
they have not been tested for interactions with ERCC3.
p53 and ERCC3 antibodies were able to co-immunopreci-
pitate ERCC3 and p53 complexes (Fig. 7, lanes 1–9).
Consistently, reduced association of p53V143A with NS5A
Fig. 7. NS5A disrupts the p53–ERCC3 complex formation in vitro. Co-immunoprecipitation of 35S-ERCC3 and wild-type p53 (lane 1) and its mutants V143A
(lane 2), R175H (lane 3), R248W (lane 4) and R273H (lane immunoprecipitation was performed using either a-ERCC3 (lanes 1–5) or a p53 (lanes 6–9).
Both ERCC3 and p53 antibodies were able to immunoprecipitate the p53–ERCC3 complexes (lane 1–9). Lanes 10–14, 100 ng of GST–NS5A added in the
reaction mixture followed by IP with a-p53. p53 mutant V143A (reduced binding with NS5A) associated with ERCC3 with similar affinities like WT p53, in
the presence of NS5A (lane 10). NS5A inhibited the interactions of other p53 mutants, R175H (lane 11), R248W (lane 12), R273H (lane 13) and wild-type p53
(lane 14) with ERCC3 . Lanes 15–18, control without antibodies to show the specificity of p53–ERCC3 complexes.
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directly correlated with the inability of NS5A to influence
p53V143A–ERCC3 interactions. NS5A did not affect
ERCC3 associations with p53 mutant V143A (Fig. 7, lane
10), since this mutant of p53 binds significantly less with
GST–NS5A (Fig. 4, lane 2). However, in the presence of
NS5A, WT p53 (Fig. 7, lane 14) and other p53 mutants
R175H (lane 11), R248W (lane 12), and R273H (lane 13)
failed to associate with ERCC3.
4.5.2. NS5A complexes with TBP and abrogates the p53–
TBP associations
To further confirm the specificity of NS5A–TBP asso-
ciations in vivo and to determine the effects of NS5A on
TBP–p53 complex formation, protein–protein complexes
were isolated by immunoprecipitation in the presence or
absence of NS5A (Fig. 8A). Confluent HCT116 p53+/ + cells
were transfected with either control empty plasmid
pCDNA3.1 (lane 1) or TBP expression plasmid pRC/TBP
(lane 2) or cotransfected with pRC/TBP plus pCDNA/NS5A
for human TBP and NS5A expression, respectively. This
was followed by metabolic labeling with 35S-[methionine]
and immunoprecipitation using p53 antibodies. As expected
TBP band was able to co-immunoprecipitate by its associ-
ation with p53 (lane 1). Two other bands of f 85
andf 130 kDa also bound p53; the authenticity of these
interacting bands is not known. ERCC3 is a 89-kDa protein
and antibodies to ERCC3 were not reactive to f 85-kDa
band shown in Fig. 8A. This could be due to low amount of
ERCC3 present in the nuclear extracts or the occupancy of
ERCC3 binding site by TBP on the p53 molecules. p53–
TBP complex formation was observed both in pCDNA3.1
control plasmid (lane 1) and pRC/TBP-transfected HCT116
p53+/ + cell line (lane 2), suggesting that endogenous TBP is
Fig. 8. (A) NS5A abrogates the p53–TBP associations in vivo.
Immunoprecipitation of 35S-[methionine]-labeled HCT116 p53+/ + cell
extracts using a-p53. Lane 1, transfected with pCDNA3.1. Lane 2,
transfected with pRC/TBP. Lane 3, cotransfected with pRC/TBP and
pCDNA/NS5A. In lane 3, no p53–TBP complex formation was observed
in the presence of NS5A. The authenticity of other p53 interacting bands is
not known. (B) Coimmunoprecipitation of TBP–p53 complex in the
presence of NS5A in vitro. Lane 1,35S-TBP alone. Lane 2,35S-TBP and 35S-
p53 mixed in a reaction buffer as described in Section 2, followed by IP
with a-TBP antibodies. Lanes 2 and 3, immunoprecipitation of TBP–p53
complexes, in the presence of either 50 ng of purified GST (lane 2) or an
unrelated GST-fusion protein GST-STAT5b (lane 3). Lanes 4–7, immuno-
precipitation of TBP–p53 complexes in the presence of increasing
concentrations of purified GST-NS5A (1, 5, 10 and 50 ng; lanes 4–7,
respectively). In lanes 4–7, increasing concentration GST–NS5A reduces
the TBP–p53 complex formation of NS5A. (C) Associations of p53 with
NS5A in vivo. The immunoprecipitation of pCDNA/NS5A transfected
HCT116 p53 /  (lane 1), and HCT116 p53+/ + (lane 2) cell extracts with a-
NS5A, followed by immunoblotting with a-p53. (D) Immunoblotting of
(C) with a-NS5A. Expression levels of NS5A are similar in pCDNA/
NS5A-transfected HCT116 p53 / (lane 1) and HCT116 p53+/ + (lane 2)
cell lines. In both cases, monoclonal antibodies against NS5A specifically
identified a doublet band of f56 and 58, the latter is a hyperphosphory-
lated form of p56.
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sufficient to form a complex with p53. However, in the
presence of NS5A, no p53–TBP complex formation was
observed in vivo (lane 3).
In an alternative approach, 35S-labeled TBP and p53
proteins were mixed in the presence of either 50 ng of GST
(Fig. 8B, lane 2) or increasing concentrations of GST–
NS5A (1, 5, 10 and 50 ng; lanes 4–7, respectively) followed
by immunoprecipitation with TBP antibodies. At concen-
trations of 10 ng (lane 6) and 50 ng (lane 7) of GST–NS5A,
TBP– p53 protein – protein complex formation was
inhibited. Addition of 50 ng of either GST (lane 2) or an
unrelated GST-fusion protein GST–STAT5b (lane 3) had no
effect on TBP–p53 associations. Based on these in vivo and
in vitro experiments, we conclude that NS5A may have
sequestered the TBP by binding; therefore, it may have
prevented the p53–TBP complex formation.
4.5.3. Associations of p53 with NS5A in vivo
Next, we studied the p53–NS5A complex formation in
vivo. NS5A expression plasmid pCDNA/NS5A was trans-
fected into HCT116 p53 / (Fig. 8C, lane 1) and HCT116
p53+/ + (lane 2) cell lines and cell extracts were subjected to
immunoprecipitation with a-NS5A. Afterward, NS5A
bound proteins were separated by SDS-PAGE, followed
by immunoblotting with a-p53. Only in p53+/ + cells, an
expected p53 band was seen. These results further confirm
the specificity of NS5A associations with p53 in vivo. The
expression of NS5A in both p53+/ + and p53 / cells was
confirmed by Western blotting of the same blot by a-
NS5A. Equal expression levels of NS5A were observed
in both p53 / and p53+/ + cells (Fig. 8D, lanes 1 and 2,
respectively).
4.6. NS5A down-regulates the p53 responsive promoters
Next, we examined the relevance of NS5A–p53 complex
formation on the p53-dependant promoter activity in vivo.
We used two approaches. First, simian virus 40 (SV40)
promoter containing multiple p53 consensus binding sites
(p53–LUC) was tested for the luciferase activity in the
presence of NS5A in HCT116 p53+/ + cell line. An f4.5-
fold increase in the luciferase activity of p53 responsive
promoter (p53–LUC) was seen when compared with the
minimal SV40 promoter construct pGL3LUC (Fig. 9A,
compare bars 1 and 2). In the presence of NS5A the p53
transactivation activity of p53 responsive promoter p53–
LUC was reduced to background levels similar to pGL3LUC
(Fig. 9A, bar 3). No changes in luciferase activity were seen
in HCT116 p53 / cell line (data not shown).
In the second approach, we used plasmid pWWP–LUC
containing the full-length human p21 (p53 responsive) pro-
moter to express the reporter luciferase gene [6]. The lucife-
rase activities of pCDNA/NS5A-transfected HCT116 p53+/ +
cells were assayed. Consistent with earlier observations,
increasing concentrations of NS5A reduce the p21 promoter
activity by f 7-fold (Fig. 9B). To eliminate the possibility of
the quenching effects of cytomegalovirus (CMV) promoter
by NS5A expression plasmid pCDNA/NS5A, 2 Ag of empty
plasmid pCDNA3.1 (containing only the CMV promoter)
was added as a control along withWWP–LUC. These results
further delineate the mechanism of p21 down-regulation in
the context of early observation that NS5A inhibits the DNA
sequence-specific binding of p53 (Fig. 5, lane 8). It is known
that p21 regulation is directly attributed to p53 binding on the
promoter [6].
Fig. 9. NS5A inhibits p53-activated transcription in vivo. (A) Luciferase activity of HCT/p53+/ +cell lines transfected with plasmids pGL3–LUC (bar 1), p53–
LUC (bar 2) and p53–LUC and pCDNA/NS5A (bar 3). A fivefold increase in the luciferase activity was observed in p53–Luc plasmid in comparison with
pGL3. However, in the presence of NS5A, this transactivation was repressed to the background level. To eliminate the quenching effects of CMV–NS5A
expression plasmid (pCDNA/NS5A), an empty vector pCDNA3.1 carrying only HCMV promoter was added along with pGL3–LUC or p53–LUC as
described in Section 2. (B) NS5A decreases the activity of p21 (p53 responsive) promoter in vivo. The effect of NS5A expression on p21 promoter was
measured in the presence of increasing concentration of NS5A expressing plasmid pCDNA/NS5A (0.5, 1.0 and 2.0 Ag, as indicated). As expected NS5A
inhibited the p21 activity by f 7-fold. ). Empty vector pCDNA3 (2.0 Ag) was also added in pWWP–LUC. Both in A and B, the relative luciferase activity/
renilla is presented. This is the mean of three independent transfection experiments.
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5. Discussion
Previous studies have identified that NS5A interacts with
a number of cellular factors including Grb2 [45], IFN-
inducible double-stranded-RNA-dependent protein kinase
(PKR) [14], C terminus of hVAP-33 (SNRE-like protein)
[50] and a novel cellular transcriptional factor, SRCAP [13].
These properties suggest that NS5A may have biological
role(s) to play with potential implications in nuclear and
cytoplasmic compartments of hepatocytes. In spite of these
observations, the precise physiological role of NS5A is not
defined. In this study we demonstrate the associations of
NS5Awith cellular TBP and p53 proteins. p53 participates in
transcription, cell cycle checkpoints, DNA repair, and apop-
totic pathways and regulates homeostatic tissue renewal
[29,34]. In eukaryotes, transcription initiation is dependent
on TBP binding to TATA box, which is the first pivotal step
in the assembly of preinitiation complex assembly (PIC)
[49]. It is now widely acknowledged that perturbations of
TBP or p53 functions have drastic effects on a wide variety
of cellular processes. Our findings of NS5A functional
association with TBP and p53 are important, since they
provide important clues into the potential mechanism(s) by
which NS5A can alter key cellular processes in HCV-
infected hepatocytes. NS5A may accomplish various cellular
functions depending upon the availability of different cellu-
lar protein(s) and or different physiological environments
during the course of HCV infection.
A deletion mutant of TBP lacking the carboxyl terminus
of 145-amino-acid residues failed to interact with NS5A,
suggesting the importance of the C terminus of TBP for
interaction with NS5A. It is important to note that like HCV,
other RNA viruses such as poliovirus are also evolved to
inactivate cellular TBP functions [4,52,53]. First, polio-
encoded protease 3Cpro can proteolytically cleave TBP to
inhibit TBP–TATA box complex formation, which shuts off
the basic transcription [52]. In an alternative way, polio-
encoded 2Apro partially cleaves TBP and does not inhibit
host cell RNA pol transcription [53]. It remains to be seen
what TBP-dependent genes are effected by NS5A in HCV-
infected hepatocytes.
Similarly, a p53 point mutant V143A showed signifi-
cantly reduced binding with NS5A, suggesting the impor-
tance of N-terminal Valine-143 residue of p53 for
interactions. The inability of p53V143A to associate with
NS5A directly correlated with the inability of NS5A to
influence p53–ERCC3 interactions. In the case of wild-type
p53 and its mutants R175H, R248W and R273H, normal
associations occurred with NS5A, thus, ERCC3 could not
form critical complex with p53. Based on these results, we
hypothesize that NS5A may have occupied the ERCC3
binding site on p53 by directly binding to it, therefore
preventing the ERCC3 to form a stable complex between
p53 and ERCC3, an integral component of transcription and
cell cycle. The p53 mutants used in this study have been
shown to abrogate p53 binding to DNA, transactivation and
its oligomerization; however, they have not been tested for
interaction with ERCC3.
It is known that p53 mediates its effects on transcription
via interactions with factors such as TBP [28,41] and ERCC3
[26]. ERCC3 is an ATP-dependent DNA helicase, which is
involved in transcription and transcription-coupled DNA
repair, a key cellular defense against DNA damage [3].
Majumder et al. [30] have recently identified the N
terminus (33–88 residues) of p53 critical for interaction
with NS5A. Although NS5A did not physically interact with
ERCC3, it interferes in the p53–ERCC3 complex formation
by interaction with p53. In contrast, hepatitis B virus (HBV)
HBx regulatory protein directly associates with ERCC3 [36]
and p53 [10] and has been shown to inhibit p53–ERCC3
complex formation in vitro [51]. Our results are consistent
with the hypothesis that NS5A has the ability to influence
transcription of key cellular genes that may be dependent on
TBP and p53 in HCV-infected hepatocytes [31,21,30].
Furthermore, NS5A’s ability to inhibit p53–TBP and
p53–ERCC3 interactions may have a pronounced impact
on transcription-coupled DNA excision repair. The finding
that p53–ERCC3 complex formation is inhibited in the
presence of NS5A could be significant, since both p53 and
ERCC3 play a pivotal role in transcription-coupled DNA
excision repair [28,44]. p53 is thought to modulate cellular
gene transcription by interacting with GTFs such as TBP
[28], hTAFii40, hTAFii60 [48] and ERCC3 component of
TFIIH [26]. The functional activities of GTFs may also be
influenced by viral and cellular transactivator proteins [49].
Upon binding to GTFs, transactivator proteins can either
modulate the assembly of preinitiation complex assembly
(PIC), a pivotal step during transcription, or promote stabil-
ity of high order protein–protein complex assembly with
the tissue specific factors. We propose that NS5A may
disrupt important protein–protein interactions and DNA–
protein complex formation on DNA that are dependent on
TBP and p53. The physiological consequence of these
perturbations in the context of HCV infection remains to
be investigated.
Clearly, NS5A inhibited the activities of p53-responsive
promoters in vivo. The down-regulation of p21 promoter
may be due to the interaction of NS5A with p53, possibly
blocking the access of p53 to the p21/WAF promoter.
Interestingly, HCV core protein has also been shown to
repress the p21/WAF promoter activity [37].
Other viral proteins such as SV40 T antigen, [25],
adenovirus E1B 55-kDa [38,54], human papilloma E6 [8],
Epstein–Barr virus EBNA [44] and HBV HBx [10] have
been shown to interact with p53 to inactivate its functions.
Interestingly, we observed that NS5A inhibited p53 associ-
ations with TBP and ERCC3 component of TFIIH, suggest-
ing that NS5A may adversely affect the p53’s ability to
participate in transcriptional regulation and transcription-
coupled DNA excision repair. p53 is thought to stall tran-
scription by interacting with either TBP or ERCC3, upon
DNA damage and then induces the preferential repair of
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damaged DNA within actively transcribed genes [3,7,39].
Since, both p53 and ERCC3 are involved in DNA repair,
any perturbations on their abilities to form complex with
DNA or proteins could lead to a compromised DNA repair.
We hypothesize that functional inactivation of p53 by HCV
NS5A may increase the mutation frequency of important
cellular genes and increase the probability of neoplastic
transformation. In the context of viral infection, the signifi-
cance of NS5A functional associations with either p53 or
TBP could not be easily understood, due to the lack of a
suitable cell culture system for HCV infection. The ultimate
understanding of the liver gene expression profile in HCV-
infected hepatocytes and the pathogenesis of HCV-related
disease remains challenging.
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